Literature DB >> 1623451

Clinically non-functioning human pituitary adenomas.

S L Asa1, K Kovacs.   

Abstract

Clinically non-functioning pituitary adenomas are morphologically classified into two groups, those which have hormone immunoreactivity and ultrastructural features of known adenohypophysial cell types but are clinically silent, and those composed of cells that do not resemble nontumorous adenohypophysial cell types. Among the former are the silent somatotroph adenomas, silent corticotroph adenomas and silent gonadotroph adenomas; the latter include the silent type III adenomas, null cell adenomas and oncocytomas. We review their histological, immunohistochemical and ultrastructural features, the results of in situ hybridization to determine hormone synthesis by these tumors and data obtained from tissue culture characterizing their hormone release in vitro. Non-functioning adenomas represent a heterogeneous group. The discrepancies between morphology, immunoreactivity and lack of endocrine activity of silent adenomas are not clear. Oncocytomas are variants of null cell adenomas. We suggest that null cell adenomas and oncocytomas originate in uncommitted pluripotent precursor cells capable of undergoing multidirectional differentiation. The progenitor cells differentiate most frequently toward FSH/alpha-subunit producing cells; the mechanism of preferential differentiation is obscure.

Entities:  

Mesh:

Year:  1992        PMID: 1623451

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  7 in total

Review 1.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

2.  GH-, PRL-, POMC-, beta-TSH-, beta-LH-, beta-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data.

Authors:  A Münscher; M Schmid; W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

3.  Proliferation markers in different types of clinically non-secreting pituitary adenomas.

Authors:  S Schreiber; W Saeger; D K Lüdecke
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

4.  Computer-Assisted Microscope Analysis of Feulgen-Stained Nuclei in Gonadotroph Adenomas and Null-Cell Adenomas of the Pituitary Gland.

Authors:  M. Beatriz S. Lopes; Isabelle Salmon; Nathalie Nagy; Christine Decaestecker; Jean-Lambert Pasteels; Edward R. Laws; Robert Kiss
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

5.  Malignant adenohypophysis spindle cell oncocytoma with repeating recurrences and a high Ki-67 index.

Authors:  Xiangyi Kong; Dongmei Li; Yanguo Kong; Dingrong Zhong
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  TMT-based quantitative proteomics revealed follicle-stimulating hormone (FSH)-related molecular characterizations for potentially prognostic assessment and personalized treatment of FSH-positive non-functional pituitary adenomas.

Authors:  Ya Wang; Tingting Cheng; Miaolong Lu; Yun Mu; Biao Li; Xuejun Li; Xianquan Zhan
Journal:  EPMA J       Date:  2019-08-29       Impact factor: 6.543

7.  Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609.

Authors:  Bo Wu; Shanshan Jiang; Xinhui Wang; Sheng Zhong; Yiming Bi; Dazhuang Yi; Ge Liu; Fangfei Hu; Gaojing Dou; Yong Chen; Yi Wu; Jiajun Dong
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.